Status:
COMPLETED
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
ViroPharma
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus conco...
Eligibility Criteria
Inclusion
- Infection with HCV genotype 1.
- HCV- infected subjects naive to treatment.
- HCV-infected non-responder subjects.
Exclusion
- Women who are pregnant or breastfeeding.
- ALT \>/ or = 5X the upper limit of normal.
- AST \>/ or = 5X the upper limit of normal.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT00367887
Start Date
October 1 2006
End Date
July 1 2008
Last Update
February 11 2013
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States, 92801
2
Pfizer Investigational Site
La Jolla, California, United States, 92037
3
Pfizer Investigational Site
La Jolla, California, United States, 92067
4
Pfizer Investigational Site
Los Angeles, California, United States, 90033